Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Aytu Biopharma (AYTU) Short-Term Debt issuances (2021 - 2026)

Aytu Biopharma has reported Short-Term Debt issuances over the past 5 years, most recently at -$5.8 million for Q4 2025.

  • Quarterly Short-Term Debt issuances fell 2147.29% to -$5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, up 69.56% year-over-year, with the annual reading at $6.7 million for FY2025, 701.44% up from the prior year.
  • Short-Term Debt issuances was -$5.8 million for Q4 2025 at Aytu Biopharma, down from $5.8 million in the prior quarter.
  • Over five years, Short-Term Debt issuances peaked at $42.2 million in Q3 2021 and troughed at -$43.0 million in Q4 2021.
  • The 5-year median for Short-Term Debt issuances is $119500.0 (2022), against an average of $63388.9.
  • Year-over-year, Short-Term Debt issuances plummeted 2165.42% in 2023 and then surged 983.96% in 2025.
  • A 5-year view of Short-Term Debt issuances shows it stood at -$43.0 million in 2021, then skyrocketed by 98.47% to -$658000.0 in 2022, then skyrocketed by 71.28% to -$189000.0 in 2023, then plummeted by 36.51% to -$258000.0 in 2024, then crashed by 2147.29% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Short-Term Debt issuances are -$5.8 million (Q4 2025), $5.8 million (Q3 2025), and -$965000.0 (Q2 2025).